Instil Bio, Inc. Operating Cash Flow
Instil Bio, Inc. (TIL) reported Operating Cash Flow of -$5.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Instil Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$4.64M.
- Instil Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.34M.
- Instil Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$7.08M.
- Instil Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$10.56M.
- Instil Bio, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$36.62M.
- Instil Bio, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$55.70M.
- Instil Bio, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$82.03M.
- Instil Bio, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$180.16M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$5.98M 10-Q · filed 2026-08-13 | -$13.05M derived: sum of 3 quarters · filed 2026-08-13 | -$23.61M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.34M 10-Q · filed 2026-05-15 | -$8.41M derived: sum of 2 quarters · filed 2026-05-15 | -$18.97M derived: sum of 3 quarters · filed 2026-05-15 | -$33.76M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$17.63M derived: sum of 2 quarters · filed 2026-03-27 | -$32.42M derived: sum of 3 quarters · filed 2026-08-13 | -$36.62M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$10.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$25.35M derived: sum of 2 quarters · filed 2026-08-13 | -$29.54M 10-Q · filed 2025-11-13 | -$40.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$14.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$18.99M 10-Q · filed 2026-08-13 | -$29.55M derived: sum of 3 quarters · filed 2026-08-13 | -$49.68M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$4.20M 10-Q · filed 2026-05-15 | -$14.75M derived: sum of 2 quarters · filed 2026-05-15 | -$34.89M derived: sum of 3 quarters · filed 2026-05-15 | -$45.50M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$10.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$30.69M derived: sum of 2 quarters · filed 2026-03-27 | -$41.30M derived: sum of 3 quarters · filed 2026-03-27 | -$55.70M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$20.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$30.75M derived: sum of 2 quarters · filed 2025-11-13 | -$45.14M 10-Q · filed 2025-11-13 | -$58.52M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$10.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$25.00M 10-Q · filed 2025-08-13 | -$38.38M derived: sum of 3 quarters · filed 2025-08-13 | -$52.81M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$14.39M 10-Q · filed 2025-05-13 | -$27.77M derived: sum of 2 quarters · filed 2025-05-13 | -$42.20M derived: sum of 3 quarters · filed 2025-05-13 | -$61.76M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$13.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$27.81M derived: sum of 2 quarters · filed 2025-03-04 | -$47.37M derived: sum of 3 quarters · filed 2025-03-04 | -$82.03M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$14.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$33.99M derived: sum of 2 quarters · filed 2024-11-13 | -$68.65M 10-Q · filed 2024-11-13 | -$105.62M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$19.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$54.22M 10-Q · filed 2024-08-13 | -$91.20M derived: sum of 3 quarters · filed 2024-08-13 | -$132.07M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$34.66M 10-Q · filed 2024-05-10 | -$71.64M derived: sum of 2 quarters · filed 2024-05-10 | -$112.52M derived: sum of 3 quarters · filed 2024-05-10 | -$159.78M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$36.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$77.85M derived: sum of 2 quarters · filed 2024-03-21 | -$125.11M derived: sum of 3 quarters · filed 2024-03-21 | -$180.16M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$40.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$88.14M derived: sum of 2 quarters · filed 2023-11-13 | -$143.19M 10-Q · filed 2023-11-13 | -$185.98M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$47.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$102.31M 10-Q · filed 2023-08-14 | -$145.10M derived: sum of 3 quarters · filed 2023-08-14 | -$174.50M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$55.05M 10-Q · filed 2023-05-11 | -$97.84M derived: sum of 2 quarters · filed 2023-05-11 | -$127.24M derived: sum of 3 quarters · filed 2023-05-11 | -$159.46M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$42.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$72.19M derived: sum of 2 quarters · filed 2023-03-31 | -$104.41M derived: sum of 3 quarters · filed 2023-03-31 | -$122.14M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$29.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$61.62M derived: sum of 2 quarters · filed 2022-11-14 | -$79.35M 10-Q · filed 2022-11-14 | -$96.17M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$32.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$49.95M 10-Q · filed 2022-08-12 | -$66.78M derived: sum of 3 quarters · filed 2022-08-12 | -$74.01M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$17.73M 10-Q · filed 2022-05-16 | -$34.55M derived: sum of 2 quarters · filed 2022-05-16 | -$41.79M derived: sum of 3 quarters · filed 2022-05-16 | -$45.06M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$16.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$24.06M derived: sum of 2 quarters · filed 2022-03-07 | -$27.33M derived: sum of 3 quarters · filed 2022-03-07 | -$29.62M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$7.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$10.51M derived: sum of 2 quarters · filed 2021-11-15 | -$12.79M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$5.56M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$2.28M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |